A Phase 4 interventional study of Metronidazole vaginal suppositories and Metronidazole vaginal suppositories and Probiotics(Umeta-mimi) in Bacterial Vaginosis, sponsored by Peking University Shenzhen Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Peking University Shenzhen Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Vaginosis, Bacterial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Vaginosis, Bacterial · China.
Among the 16 studies in Vaginosis, Bacterial with a site in China, this one is the 6th largest by planned enrollment, is the only one that started in 2020, is one of 6 in phase 4, and was the 7th registered.
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
Browse Vaginosis, Bacterial studies →6 of the 16 studies in Vaginosis, Bacterial with a site in China are open now. Recruiting first, the newest first:
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–50 · Women only
Zhujiang Hospital · Sites in China
Ages 18–55 · Women only
SPH Sine Pharmaceutical Laboratories Co., Ltd. · Sites in China
Ages 18–55 · Women only
Chengdu Syncor Pharmaceutical Co., Ltd. · Sites in China
Ages 18–50 · Women only
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 140 is above the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Median enrollment 123 across the 16 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 10 most frequent:
Peking University Shenzhen Hospital is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
Peking University Shenzhen Hospital has 3 studies filed under Vaginosis, Bacterial — fewer than ten, so there is no comparison to draw.
4 of the studies in Vaginosis, Bacterial with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04771728Peking University Shenzhen HospitalA Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis | 2026-12-01 |
| NCT07663838Changchun GeneScience Pharmaceutical Co., Ltd.A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) | 2027-01-05 |
| NCT07483671Chengdu Syncor Pharmaceutical Co., Ltd.Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients | 2027-01-24 |
| NCT07888699SPH Sine Pharmaceutical Laboratories Co., Ltd.WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis | 2027-10-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Vaginosis, Bacterial with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are trying to determine if oral Probiotics(Umeta-mimi,30 days) with Metronidazole vaginal suppositories (7 days) is better than using Metronidazole vaginal suppositories(7 days) only in preventing the recurrence of bacterial vaginosis
Studies have shown that oral Probiotics(Umeta-mimi) can significantly promote the recovery of vaginal flora mainly because intestinal microbiota can migrate and affect vaginal microecology. This project aims to evaluate the efficacy of oral Probiotics(Umeta-mimi,30 days) with Metronidazole vaginal suppositories(7 days) in the treatment of bacterial vaginosis (BV) and to explore the correlation between vaginal flora and fecal flora by detecting the metagenomics of vaginal secretions and intestinal feces at the time of baseline phase,14 days after treatment, the first month after treatment, 5-7 days after third menstruation after treatment and 5-7 days after sixth menstruation after treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
Drug: Metronidazole vaginal suppositories
Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days)
Drug: Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)
Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days)
Also known as: Metronidazole vaginal suppositories adn Probiotics(Umeta-mimi)
Cure rate of BV
Assessments with different Units of Measure:clinical symptoms such as itching or burning; "fishy" smell; homogeneous thin vaginal discharge;Nugent score; pH\>4.5; clue cell.
Time frame: 14 days after treatment
Recurrence of BV
Nugent score
Time frame: The first month after treatment
Recurrence of BV
Nugent score
Time frame: 5-7 days after third menstruation after treatment
Recurrence of BV
Nugent score
Time frame: 5-7 days after sixth menstruation after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Dec 2026, 82 months after the start.
Of 17 phase 4 interventional studies under Vaginosis, Bacterial, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 41. This study's planned 82 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Shenzhen Hospital